MX2021003689A - Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp). - Google Patents
Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp).Info
- Publication number
- MX2021003689A MX2021003689A MX2021003689A MX2021003689A MX2021003689A MX 2021003689 A MX2021003689 A MX 2021003689A MX 2021003689 A MX2021003689 A MX 2021003689A MX 2021003689 A MX2021003689 A MX 2021003689A MX 2021003689 A MX2021003689 A MX 2021003689A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrugs
- cgrp antagonists
- cgrp
- pharmaceutical compositions
- antagonists
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 229940127597 CGRP antagonist Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen fármacos precursores de antagonistas de CGRP, métodos de tratamiento de trastornos relacionados con CGRP, por ejemplo, migraña, mediante la administración a un paciente en necesidad del mismo de fármacos precursores, composiciones farmacéuticas que comprenden los fármacos precursores que incluyen las composiciones farmacéuticas e instrucciones para uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745302P | 2018-10-13 | 2018-10-13 | |
| PCT/US2019/055525 WO2020077038A1 (en) | 2018-10-13 | 2019-10-10 | Prodrugs of cgrp antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003689A true MX2021003689A (es) | 2021-06-04 |
Family
ID=70164029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003689A MX2021003689A (es) | 2018-10-13 | 2019-10-10 | Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12030868B2 (es) |
| EP (1) | EP3863629A4 (es) |
| JP (1) | JP7295944B2 (es) |
| KR (1) | KR20210078507A (es) |
| CN (1) | CN112888438A (es) |
| AU (1) | AU2019357507A1 (es) |
| BR (1) | BR112021005873A2 (es) |
| CA (1) | CA3115779A1 (es) |
| EA (1) | EA202190966A1 (es) |
| IL (1) | IL281448A (es) |
| MX (1) | MX2021003689A (es) |
| PH (1) | PH12021550671A1 (es) |
| SG (1) | SG11202102648UA (es) |
| WO (1) | WO2020077038A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024062504A1 (en) * | 2022-09-22 | 2024-03-28 | Quisitive Therapeutics | Pharmaceutical composition comprising ubrogepant and administration thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1812982B (zh) * | 2003-06-26 | 2010-10-27 | 默沙东公司 | 苯并二氮杂*cgrp受体拮抗剂 |
| RU2009125597A (ru) | 2006-12-05 | 2011-01-20 | Ньюроджесэкс, Инк. (Us) | Пролекарства и способы их получения и применения |
| WO2009100090A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| EP2445343B1 (en) | 2009-06-25 | 2021-08-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| US20110166156A1 (en) | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease |
| CA2798172C (en) | 2010-01-07 | 2017-11-21 | Alkermes Pharma Ireland Limited | Quaternary ammonium salt prodrugs |
| US8481546B2 (en) | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US9227973B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
| CN106478596A (zh) | 2015-08-25 | 2017-03-08 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
| WO2018178938A1 (en) | 2017-03-31 | 2018-10-04 | Heptares Therapeutics Limited | Cgrp receptor antagonists |
-
2019
- 2019-10-10 EA EA202190966A patent/EA202190966A1/ru unknown
- 2019-10-10 KR KR1020217013969A patent/KR20210078507A/ko active Search and Examination
- 2019-10-10 EP EP19870703.6A patent/EP3863629A4/en active Pending
- 2019-10-10 SG SG11202102648UA patent/SG11202102648UA/en unknown
- 2019-10-10 AU AU2019357507A patent/AU2019357507A1/en not_active Abandoned
- 2019-10-10 JP JP2021520219A patent/JP7295944B2/ja active Active
- 2019-10-10 WO PCT/US2019/055525 patent/WO2020077038A1/en unknown
- 2019-10-10 MX MX2021003689A patent/MX2021003689A/es unknown
- 2019-10-10 CA CA3115779A patent/CA3115779A1/en active Pending
- 2019-10-10 CN CN201980067352.XA patent/CN112888438A/zh active Pending
- 2019-10-10 BR BR112021005873-7A patent/BR112021005873A2/pt unknown
- 2019-10-10 US US17/283,049 patent/US12030868B2/en active Active
-
2021
- 2021-03-11 IL IL281448A patent/IL281448A/en unknown
- 2021-03-25 PH PH12021550671A patent/PH12021550671A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021550671A1 (en) | 2021-12-13 |
| EP3863629A4 (en) | 2022-06-22 |
| EA202190966A1 (ru) | 2021-10-15 |
| SG11202102648UA (en) | 2021-04-29 |
| CN112888438A (zh) | 2021-06-01 |
| BR112021005873A2 (pt) | 2021-07-27 |
| CA3115779A1 (en) | 2020-04-16 |
| JP7295944B2 (ja) | 2023-06-21 |
| US12030868B2 (en) | 2024-07-09 |
| US20210395223A1 (en) | 2021-12-23 |
| WO2020077038A1 (en) | 2020-04-16 |
| JP2022512687A (ja) | 2022-02-07 |
| AU2019357507A1 (en) | 2021-05-27 |
| EP3863629A1 (en) | 2021-08-18 |
| IL281448A (en) | 2021-04-29 |
| KR20210078507A (ko) | 2021-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| NZ737399A (en) | Ccr2 modulators | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| EA202191115A1 (ru) | Новые пиридазины | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
| PH12017501736A1 (en) | Indole derivatives | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| EA202092278A1 (ru) | Римегепант для связанных с cgrp расстройств | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| TR201719926A2 (tr) | Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler |